Landos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial Cells

14 Sep 2023
www.globenewswire.com
Phase 2Immunotherapy
Landos Biopharmaa, Inc. (NASDAQ: LABP), a clinical-stage biopharmKU Leuven company developing novel, oral medicines for patients with autoimmune dNX-13es, today announced a strategic research collaboration to investigate the effects of NX-13 on epithelial cells with the Inflammatory Bowel Disease (IBD) Team at KU Leuven and University Hospitals Leuven (KU Leuven), a leading European research university and hospital network known for its innovation in Leuven, Belgium.
NX-13 is the first-in-class, oral, gut-selective, NLNX-13goni
Ulcerative Colitis
mechanism of action that addresses both extracellular signals and the intracellular environment to reduce pro-inflammatory signals restore immune and microbiome balance and improve epithelial barrier integrity. The NEXUS Phase 2 proof-of-concept clinical trial of NX-13 in patients with moderate-to-severe ulcerative colitis (UC) was initiated during the second quarter of 2023. Recruitment, screening and randomization of patients continues, with top-line results on track for the fourth quarter of 2024.
Bram Verstockt, M.D., Ph.D., an assistant profeLandos Biopharma, Inc.t at KU Leuven, will lead the research collaboration together with professor Séverine Vermeire, M.D., Ph.D., ai
autoimmune diseases
he direct effects of NX-13 in epithelial cells by using UC patient-derived organoidNX-13ls. These organoid models are
Inflammatory Bowel Disease (IBD)
ing formed mucosal and epithelial layers that mimic in vivo conditions while allowing for controlled in vitro studies. The results are expected to provide further insight into the impact of NX-13 on gene expression and regulation, and cytokine responses.
NX-13re thrilled to collaborate with Dr. Verstockt
NLRX1
the IBD Team at KU Leuven, an established global research center at the leading edge of clinical and translational research,” commented Dr. Fabio Cataldi, Executive Vice-President & Chief Medical Officer at Landos. “We expect this research will broaden our already strong data foundation NX-13he novel and unique bimodal mechanism
ulcerative colitis (UC)
further validate the role of immunometabolism in inflammation and IBD.
“We look forward to collaborating with Landos on NX-13 a
IBD
believe our patKU Leuvenved organoid models are the right system to measure the effect of NX-13 on epithelial cells. We are hoping that the learnings from this rNX-13ch collaboration will support
UC
e potential of NX-13 in breaking the vicious inflammatory cycle in UC, which remains a significant unmet need in effectively treating patients,” concluded Dr. Verstockt.NX-13
Landos expects to present results from this research collab
IBD
tion at aKU Leuvene medical conferences in 2024.LandosNX-13
inflammation
IBD
About Landos BiopharmaNX-13NX-13NX-13
UC
Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class, oral therapeutics for patients with autoimmune diseases. Our mission is to create safer and more effective treatments that address the therapeutic gap in the current treatment paradigm.
We havLandos Biopharma novel targets anchoring two libraries of immunometabolic modulation pathways, including four potentially first-in-class, once-daily, oral therapies targeting eight indications in the immunology space.
Landos Biopharma focused on advancing the clinical development of NX-13 in UC. We initiated the NEXUS Phase 2 proof-of-concept trial in the secon
autoimmune diseases
nd expect to report topline results by the fourth quarter of 2024.
About KU Leuven and University Hospitals Leuven
KU Leuven is Europe’s most innovative university (Reuters) and ranNX-13nd i
UC
the Times Higher Education World University Rankings. As Belgium's largest university, KU Leuven welcomes 65,000 students from over 140 countries. Its nearly 8,000 researchers are active in a comprehensive range of disciplines. KU Leuven is a founding member of the League of European Research Universities (LERU) and has a strong European and international orientation. University Hospitals Leuven, its network of research hospitals, provides high-quality healthcare and develops new therapeutic and diagnostic insights with an emphasis on translational research.
The content above comes from the network. if any infringement, please contact us to modify.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Colitis, Ulcerative,Autoimmune Diseases,Inflammatory Bowel Diseases
[+1]
Targets
NLRX1
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.